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Acute ischemic stroke imaging is one of the leading causes of death and disability worldwide. Neuroimaging plays a crucial role in
early diagnosis and yields essential information regarding tissue integrity, a factor that remains a key therapeutic determinant. Given
the widespread public health implications of stroke and central role of neuroimaging in overall management, acute stroke imaging
remains a heavily debated, extensively researched, and rapidly evolving subject. There has been recent debate in the scientific
community due to divided opinions on the use of CT perfusion and access-related limitations of MRI. In this paper we review
and summarize recent updates relevant to acute stroke imaging and propose an imaging paradigm based on the recently available
evidence.
1. Introduction
Acute ischemic stroke is one of the leading causes ofmortality
and morbidity worldwide. Statistics from the American
Heart Association estimate an average of 1 stroke every 40
seconds in the United States amounting to approximately
795,000 people experiencing new or recurrent strokes, per
year [1]. In view of the widespread public health impact of
stroke and its profound impact on patients, stroke research
has remained in the forefront. A recent systematic review
article reported no significant difference between reperfusion
strategies based on the current literature, emphasizing need
for future randomized clinical trials to determine the efficacy
of alternative reperfusion strategies [2]. As noted byGonzales
R in a recent commentary, the failure to recognize relative
efficacy of treatment strategies can be partially attributed
to lack of appropriate patient selection due to ineffective,
inconsistent, and contradictory neuroimaging approach.This
was one of the potential causes that lead to the halting of the
Interventional Management of Stroke III Trial [3].
There is a critical need for reproducible and sensitive
imaging biomarkers that allow accurate assessment of efficacy
of rapidly evolving thrombolytic treatments. This under-
scores the primary need for standardization of imaging
techniques across institutions so data from multicenter trials
can be collectively analyzed. The glaring lack such consensus
amongst imaging techniques was highlighted in a recent sys-
tematic review which found wide variability in the employed
thresholds for CT and MR perfusion imaging and significant
inconsistency in definitions of tissue states; factors which add
to the widespread variability in perfusion-based assessment
[4].
Despite the inherent challenges and past failures, stroke
imaging is rapidly evolving with enormous ongoing research
and global public health impact. In this paper we sought to
review recent cumulative evidence including evolving expert
opinions and recommendation to assess the adequacy of cur-
rent state of clinical practices in acute stroke imaging. Based
on our assessment we propose an optimal imaging paradigm
for patients presenting with suspected acute ischemic stroke.
2. Identification of Target Clinical Goals in the
Acute Care Setting
The initial step in approaching the imaging paradigm is
to summarize the targeted clinical goals for patients with
suspected acute ischemic stroke in the acute care setting.
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The fundamental objective of treatment is to enable rapid
reperfusion for maximal tissue salvation. There is substantial
evidence to suggest efficacy of intravenous thrombolytic
therapy in the first 4.5 hours from onset of symptoms as
well as increased risk of hemorrhagic complications and
lower efficacy outside the therapeutic window. The Euro-
pean Cooperative Acute Stroke Study (ECASS) investigators
demonstrated the efficacy of treatment instituted within the
first 4.5 hours [5]. This was confirmed on a systematic review
with pooled data from 11 randomized controlled trials eval-
uating intravenous thrombolysis (IVT) and 3 randomized
controlled trials evaluating intra-arterial thrombolysis (IAT).
This review concluded efficacy of IVT within 4.5 hours of
onset of symptoms, beyond which the risk of treatment
outweighed the benefit. The clinical utility of expanding the
treatment window to 6 hours with IAT treatment is currently
investigational [6].
Based on the above considerations the following goals
must be achieved to allow early initiation of treatment.
The choice of imaging approach and interpretation protocol
should be designed with the intent of addressing the primary
clinical goals such as to allow safe and prompt initiation of
thrombolytic strategies.
2.1. Goal 1
Exclusion of Primary Intracranial Hemorrhage, Assessing for
Alternate Etiologies for Symptoms and Treatment Contraindi-
cations. Once the patient presents to the ER with neurolog-
ical symptoms possibly corresponding to a suspected acute
stroke, the initial goal is a “rule out” approach. This is
particularly critical in those patients with early presentation,
as they are most likely to benefit from rapid institution of
reperfusion therapy.
Initial evaluation focuses on exclusion of primary intrac-
erebral hemorrhage (PICH), intracranial metastasis, tumor
with herniation, or other alternate etiologies explaining the
clinical picture.
2.2. Goal 2
Infarct Characterization: Identifying of Core, Quantification of
Core Volume, Imaging of Penumbra and Pial Collateral Vessels.
This has been thoroughly reviewed and concisely presented
as the “core, clot, collateral” approach and is currently the
mainstay of acute stroke neuroimaging [7].
2.3. Nonenhanced Head CT. Theoretically Goals 1 and 2
can be assessed on NECT/CTA combination, which is the
most ideal single-step imaging solution. Guidelines pub-
lished by American Heart Association and American Stroke
Association Stroke Council in 2007 mandate universal and
immediate availability of nonenhanced head CT (NECT)
within 30 minutes of initial presentation to the ER [8].
There is no controversy regarding the utility of NECT
with regards to accomplishingGoal 1. In particular it is widely
accepted that NECT can reliably exclude intracranial hemor-
rhage, which is critical for therapeutic decision making.
In terms of infarct characterization to address Goal
2, NECT-based scoring system designed by the Alberta
Stroke Program, commonly referred to as the ASPECTS
scoring system, (Alberta Stroke Program Early CT Score)
provides an effective tool for quantifying early ischemic
changes in the MCA territory (Figure 1). This methodology
has provided useful prognostic information with regards to
response to reperfusion. Patients with high ASPECTS scores
(8–10) corresponding to low infarct volume on initial imaging
demonstrated the best clinical outcomes [9]. However, as
noted by Demchuck et al. the greatest limitation of ASPECTS
application is the inability to accurately visualize the early
ischemic changes on NECT in the real world setting, [7].
This is more problematic in the setting of preexisting white
matter changes. An interobserver reliability study demon-
strated a 77% concordance for total ASPECTS score with
lower agreement for scores based on a cut-off (>7 and ≤7)
and also lower agreement for cortical and internal capsule
regions [10]. Overall, there is substantial cumulative evidence
indicating ASPECTSNECT scoring as a very objective, semi-
quantitative, prognostic tool and we recommend utilization
of online resources to aid ASPECTS utilization in early acute
stroke imaging; see http://www.aspectsinstroke.com/ [11].
2.4. MRI with Diffusion-Weighted Imaging. There is conclu-
sive evidence regarding the sensitivity of MRI with diffusion-
weighted sequences for the detection of infarct core including
those cases in which the infarct core remains occult on stan-
dard T2-weighted imaging [12]. Evidence-based guidelines
proposed by the Therapeutics and Technology Assessment
subcommittee of the American Academy of Neurology,
endorses the role of DWI in accurate diagnosis of acute
ischemic stroke particularly in the first 12 hours as being
superior to NECT and also suggest, that baseline DWI infarct
volume has predictive ability towards final infarct volume and
overall clinical outcomes [13].
Recent considerations for the same were reviewed by R.
Gonzalez indicating a significant role of MRI with diffusion-
weighted sequences in identifying infarct core and allowing
assessment of core volume, which is a useful predictor of
treatment efficacy [14]. In the past, pretreatment infarct
core volume has been demonstrated to be a highly specific
predictor for malignant middle cerebral artery infarction
at a threshold core volume of greater than 82mL. [15].
The MR Stroke study group investigators found a 5.8 fold
increased risk of symptomatic intracerebral hemorrhage in
patients with large-volume infarct cores (>100mL) compared
to small (<10mL) and moderate (10–100mL) ones [16].
A core volume threshold of approximately 70mL has been
suggested as having dichotomous prognostic implications
with patients with higher core volumes having unfavorable
outcomes regardless of treatment [17, 18].
A recent study demonstrated that posttreatment final
infarct volume (FIV) also has significant influence on clinical
outcome in patients undergoing IAT [19]. This study showed
high specificity for poor outcome with FIV of >90 cm3.
Therefore with regards to established management goals, MR
with diffusion-weighted imaging provides the most accurate
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Figure 1: Obtained from http://www.aspectsinstroke.com/, demonstrating the ASPECTS scoring methodology, axial NCCT images showing
the MCA territory regions as defined by ASPECTS. C, caudate, I, insularribbon, IC, internal Capsule, L, lentiform nucleus, M1, anterior
MCAcortex, M2, MCA cortex lateral to the insular ribbon, M3, posteriorMCA cortex, M4, M5, M6 are the anterior, lateral, and posterior
MCAterritories immediately superior to M1, M2, and M3, rostral to basal ganglia. Subcortical structures are allotted 3 points (C, L, and IC).
MCA cortex is allotted 7 points (insular cortex, M1, M2, M3, M4, M5, and M6). (Reprint permission obtained from Dr. Mayank Goyal,
professor of radiology and clinical neurosciences, Foothills Medical Centre, University of Calgary).
information related to Goal 2 principles of core identification
and core volume quantification.However, diffusion-weighted
imaging alone has limited utility for detection of penum-
bra for which MR perfusion estimates are more reliable
and it provides little information about vascular substrates,
including assessment of occluded vessel and degree of pial
collateralization.
Additionally, there are accessibility issues due to individ-
ual contraindications to MR and limited availability of MRI
leading to underutilization of MRI in emergent setting. A
recent study evaluated the adherence to AAN guidelines of
preferring MR over CT in the initial 12 hours of presentation
and revealed that the target wasmet in less than 1/3 of patients
in their study [20].
2.5. Mismatch Imaging: CT Perfusion and MR Perfusion.
Perfusion imaging either CT or MR is most relevant in terms
of ability to delineate the ischemic penumbra. The clinical
utility of penumbra imaging has long remained an issue of
debate. The hypothesis of penumbra identification is that
identification of “at-risk” tissue may allow widening of the
treatment window beyond 4.5 hours and allow detection of
patients who will either benefit from treatment or those in
whom treatment is not likely to cause improved outcome.
It is notable that the recent study by the MR Rescue
investigators found no role of penumbra imaging in selecting
patients likely to benefit from endovascular therapy within 8
hours from onset of symptoms. There was evidence of good
functional outcome in patients with favorable penumbral
pattern in the late time window regardless of recanalization.
Interestingly, this study raises the possibility that patientswho
have a favorable penumbral pattern may be inherently more
resilient to the effects of vascular occlusion and therefore
harbor a favorable outcome regardless of treatment, thus
explaining lack of differential effect of therapy when stratified
on the basis of penumbral pattern [21].
Nevertheless there remains an interest in imaging
penumbra due to its potential role as a prognostic biomarker.
Previously, CT perfusion performed soon after the initial
NECT has been supported as being a safe and efficacious
strategy for imaging tissue at risk [22]. On the other hand a
recent study demonstrated low sensitivity of MTT maps in
predicting acute infarct detectable on DWI sequence. CBV
also did not correlate with the DWI abnormalities.This study
advocates against utilization of CTP in acute NVS [23].
Reliance on postprocessing, restricted brain coverage,
and vendor related-differences in processing algorithm are
primary limitations which have not yet been completely
addressed and remain as mitigating factors in enabling wider
utility of CTP. Additionally the inherent low contrast to
noise ratio increases susceptibility to artifacts and lowers
overall sensitivity. These considerations were reviewed by R.
Gonzales and for the same reasons the clinical utility of CTP
was felt to be doubtful in the current state of practice [3].
On a contrary note, a recent expert commentary by
M. Lev acknowledges the aforementioned CTP limitations
but continues to endorse this method due to its relative
cost efficacy, rapid availability, and potential for quantitative
assessment relative toMRI [24]. A recent study demonstrated
that CTP-based penumbra volume was an independent pre-
dictor of clinical outcome in 90 days alongwith recanalization
status. This study also demonstrated that the CT perfusion
based penumbra volume could not be accurately assessed by
clinical parameters, NECTorCTA [25]. CTP rCBFmapswith
appropriate threshold levels are felt to represent an accurate
estimate of the infarct core [26, 27].
4 Stroke Research and Treatment
MR perfusion parameters are equally sensitive in depict-
ing tissue at risk although expense, lack of universal applica-
bility and access issues in the ER setting remain limiting fac-
tors. Recently the applicability of MR Perfusion was reviewed
by M. Fisher, highlighting its utility in delineating tissue at
risk of infarction and thus holding promise in expansion
of the therapeutic window. A key aspect underscored in
this review relates to the identification of “benign oligemia,”
which refers to hypo perfused tissue which will not proceed
to infarction regardless of treatment. The MR perfusion
parameter 𝑇max with 𝑇max delay of >5 to 6 seconds compared
to normally perfused tissue was considered to be a useful
indicator of impending infarction in the absence of reper-
fusion [28]. Using pooled data from the DEFUSE (diffusion
and perfusion imaging evaluation for understanding stroke
evolution) and EPITHET (echoplanar imaging thrombolytic
evaluation trial) studies, Mlynash et al. found that based on
𝑇max and diffusion-determined mismatch, patients with a
mismatch who have large core volumes (size of DWI lesion)
or large perfusion defect (large-volume, severe 𝑇max delay)
had unfavorable outcomes despite reperfusion. This study
suggested a 𝑇max > 8 secs with a volume of approximately
100mL as an adequate threshold for identification of patients
with malignant profile of infarction who would be poor
candidates for reperfusion therapy [29].
2.6. CT Angiography. CT angiography continues to be the
superior method for characterization of vascular anatomy.
Figure 2 in addition to allowing for assessment of the site of
vascular occlusion, it also allows assessment of the presence of
calcifications and atherosclerotic disease, which can influence
recanalization techniques. It is also the most effective non-
invasive means of assessment of leptomeningeal collaterals,
which not only determines rate of core expansion but also
influences possibility of hemorrhagic transformation [30]. A
study by Bang et al. demonstrated higher risk of hemorrhagic
transformation in patients with poor collateral status [31].
Another study demonstrated discriminatory ability of a
poor collateral score in detecting a malignant profile (larger
DWI lesion volume at baseline, higher median NIHSS and
functional dependency at 3 months after stroke) [32].
A recent study showed that CTA evidence of occlusion
of distal internal carotid, proximal middle cerebral, or basilar
arteries as a predictor of poor outcome and added incremen-
tal predictive value to NIHSS.This suggests the utility of CTA
in early phase treatment decision making [33].
A potential confounding factor is acquisition protocol-
dependent overestimation of infarct core volume using CTA
source images for detecting of early ischemic changes [34].
The source images acquired by slow CT acquisition demon-
strated greater infarct volume correlation with MR diffusion
core estimates compared to the multislice CT scanner. This
overestimation has critical clinical implications given it may
prevent institution of reperfusion treatments in patients who
could have potentially benefited from reperfusion therapy
[34].
Overall, CTA has a definite prognostic role in acute phase
of stroke imaging. In particular, with relevance to our defined
Goal 2, acute-phase CTA can enable assessment of site of
occlusion, integrity of vessels in terms of atherosclerotic
disease, and degree of collateral flow, all of which influence
management decision making (Figure 2). It must, however,
be kept in mind that CTA entails exposure to radiation and
iodinated contrast, which are potential pitfalls of utilization.
2.7. Proposed Imaging Paradigm. Despite significant advances
in our understanding of physiologic surrogates of imaging
observations and the respective technical confounds, there
are still considerable debate and lack of consensus par-
ticularly with relevance to penumbra imaging and role of
perfusion imaging as it relates to core characterization and
penumbra estimation.
If we take a minimalist approach, the expert opinion
seems to converge most definitively on two standard queries
prior to therapeutic decision making (1) is there primary
intracranial hemorrhage? and (2) what is the volume of the
infarct core? These two components combined with clinical
neurological assessment seem to be most directly related to
clinical outcome in postperfusion recovery phase and will
help stratify patients appropriately for treatment decision-
making.
The limitation of the minimalistic approach is that
although it raises specificity, by helping us identify those that
will have a favorable outcome after-reperfusion, it also at the
same time lowers sensitivity, thereby potentially excluding
patients who may have benefitted from more aggressive
reperfusion therapy.
One of the ways to achieve efficient imaging selection
for treatment triage is development of a unimodal imag-
ing protocol. Simplistically stating, a one-stop, all-inclusive
imaging protocol can accurately and reproducibly classify
patients who will either (a) benefit from treatment or (b)
have no impact or negative impact of treatment. NECT
is the most obvious choice for Goal 1-related aspects of
management. However, beyond that it would be ideal if the
CT imaging and interpretation protocols can be optimized
in such a way that Goal 2 can be consistently and reliably
achieved in acute-phase urgent care setting on the same CT
scanner without having to transfer the patient. We believe
that in many cases this is feasible, particularly when the
ASPECTS score is carefully interpreted, providing infarct
core volume information. To assist in the latter, we encourage
the use of online resource described by Modi et al. [11]
(http://www.aspectsinstroke.com/) to optimize utilization of
NECT. This can be followed by CTA/CTP to assess the
remaining aspects of Goal 2 with relevance to site of occlu-
sion, collateral flow assessment, and penumbra imaging, all of
which have been established as either predictors of treatment
efficacy or overall clinical prognosis in poststroke recovery
phase.This approachminimizes scanner time and utilizes the
most widely available technologies only. Based on the consid-
erations presented in theGonzalez andM. Lev commentaries,
we agree that NECT with ASPECTS assessment along with
CTA can provide sufficient information for adequate triage
of patients who will benefit from treatment. The remainder
of the imaging including penumbra imaging with CTP can
be performed while the treatment implementation has begun
minimizing the “door-to-needle” time [3, 24].
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Figure 2: (a) and (b) ADC map and DWI map with restricted diffusion in the setting of cytotoxic edema from acute ischemic infarct in
right MCA territory. (c) NECT showing hyperdense right MCA compatible with acute thrombosis. (d) CTA image with thrombosis in the
corresponding segment of right MCA. (e), (f), and (g) CTP with elevated MTT, reduced cerebral blood flow, and blood volume in the right
MCA territory.
However, we acknowledge coexistent evidence that indi-
cates limitation of NECT in core characterization due to
multitude of factors including inherently low sensitivity to
early ischemic changes. It is agreed upon that core volume
is a key determinant of treatment efficacy, for which MR
with DWI is the imaging gold standard. In an ideal world
with no cost, availability or individual applicability issues,
an all inclusive MR protocol for acute stroke imaging would
be more preferred from the viewpoint of obtaining accurate
and consistent tissue specific information with minimum
susceptibility to postprocessing variability.
As stated above we emphasize that if MRI is not available
and decision for endovascular therapy has to been taken
based on the initial NECT, then immediate CTA (to assess
vessel occlusion and collateral status) and CTP (infarct core
assessment on rCBF map) should be considered (Figure 2).
This approach would require less than 10 minutes and can be
performed while the intravenous thrombolytic agent is being
initiated [3, 24].
The utility of mismatch imaging is undoubtedly promis-
ing; however, the recent body of evidence does not provide
compelling arguments to necessitate a paradigm shift partic-
ularly in routine clinical settings outside of major academic
institutions. This is especially true in light of the results
from the recent penumbra-based trial of imaging selection
by the MR Rescue investigators demonstrating no utility of
penumbra imaging in detecting patients who would benefit
from endovascular therapy of acute ischemic stroke [21].
At this timewith proven efficacy of IVTwithin the first 4.5
hours, it is notable that the frequency of thrombolytic therapy
in patients with acute ischemic stroke remains remarkably
low. A large multicenter study found only 3% utilization of
thrombolysis for all acute ischemic stroke patients and only
10% for those who presented within the first 3 hours [35].
This is largely related to complexity of imaging protocols and
a general lack of consensus amongst the experts regarding
imaging appropriateness leading to inability to select the
appropriate patients who would benefit from treatment in
a timely fashion. In light of these compelling statistics, we
strongly encourage a minimalist imaging approach, which
can be reliably and consistently reproduced regardless of
variability in institutional capabilities. NECT with ASPECT
emphasis with simultaneous CTA/CTP and prompt MR with
diffusion remain the most rigorously optimized imaging
tools.
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